The researchers would like to assess dosage efficiency through repeated titrations for a standard therapeutic threshold of 50% or greater based on liposomal binding and delivery of its interior components. If a certain percentage of tumor cells are sensitized with each dose, it will allow the researchers to further assess binding efficiencies of the liposome to its targets as well as therapeutic efficiency. Due to its phospholipid bilayer and biochemical interactions with water that hold its structure together, this liposome will be delivered intravenously to the patient suspended in an aqueous or hydrophilic solution. Hydrophilic drugs (ONC201, ABT263, and Cbl) will be located in the interior, while antibodies for pancreatic adenocarcinoma-specific antigens (CA 19-9, MUC-1, and NT5E) will be dispersed among the exterior.
Recent comments